
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics is expected to have a positive outlook in 2026, with the upcoming Phase 2b results for Halneuron in chemotherapy induced neuropathic pain (CINP) being a major catalyst. The lack of approved drugs for this indication provides a significant market opportunity for Dogwood, and further success in other pain indications could expand Halneuron's potential. In addition, the initiation of the SP16 clinical program and potential partnerships for legacy assets could provide further upside for the stock.
Bears say
Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company with a focused pipeline targeting chronic neuropathic pain and neuropathy. Despite the upcoming initiation of a Phase 1b study for SP16 targeting breast cancer patients, the lack of revenue and the novel mechanism of action for the drug raise concerns about the company's future success. In addition, initial results for the study are not expected until early-2027, delaying any potential positive developments for the stock.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares